Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Announce New Drug Prices on Aug. 19
The Ministry of Health, Labor and Welfare (MHLW) will announce new NHI prices, which will take effect on October 1 in tandem with the consumption tax hike, on August 19, informed sources said. Japan plans to shave drug prices by…
To read the full story
Related Article
- Prices Go Up for 37% of Drugs, Down or Intact for 63% in Tax Hike Re-Pricing
August 20, 2019
- Kymriah, All Checkpoint Drugs but Tecentriq to Get Price Maintenance Premium in October Re-Pricing
August 20, 2019
- MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
REGULATORY
- LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
- UK Halts Tavneos for New Patients, Approval Revocation Set for March
September 4, 2026
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…